NCT00224497已完成2 期
A Phase IIa/b Double-blind, Randomised, Placebo-controlled, Linear Trend Design Dose-ranging Study to Investigate the Effects of 24 Weeks of Monotherapy With SB-742457 on Cognition in Subjects With Mild to Moderate Alzheimer's Disease
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 380
- 试验地点
- 48
- 主要终点
- Change in cognition and function after 24 weeks.
研究概览
简要总结
The purpose of this study is to find out if SB-742457 is a safe treatment and what effects it has on the symptoms of mild to moderate Alzheimer's disease. SB-742457 is a new treatment which is thought to increase the levels of certain chemicals in the brain that are often decreased in patients with Alzheimer's disease.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 50 Years 至 85 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Clinical diagnosis of probable mild-to-moderate Alzheimer's disease as determined by the NINCDS-ADRDA and DSM-IV criteria with an MMSE score of 12-
- •Subjects and their caregivers must provide informed consent prior to study entry.
- •Adequate blood pressure and laboratory values.
排除标准
- •Females of child-bearing potential.
- •Have other causes of dementia such as vascular damage, depression, bipolar affective disorder, schizophrenia, syphilis, vitamin B12 deficiency or thyroid deficiency.
- •Subjects taking medication for Alzheimer's disease or centrally acting agents which might impact study outcomes.
- •Subjects taking agents for which there is a theoretical risk of interaction with SB-
- •Subjects with known hypersensitivity to sunlight or seizures.
结局指标
主要结局
Change in cognition and function after 24 weeks.
次要结局
- Change in behavioural symptoms, activities of daily living and caregiver burden after 24 weeks. Changes in all symptoms at 8 and 12 weeks. Safety and tolerability. PK and dose response profiling. Efficacy related to ApoE status.
研究者
研究点 (48)
Loading locations...
相似试验
已完成
2 期
SB-742457 And Donepezil In Alzheimer's DiseaseAlzheimer's DiseaseNCT00348192GlaxoSmithKline200
已完成
2 期
SB-773812 Administered In Adults With SchizophreniaSchizophreniaNCT00259870GlaxoSmithKline338
已完成
2 期
SC12267 (4SC-101) in Combination With Methotrexate in Patients With Rheumatoid ArthritisRheumatoid ArthritisNCT010105814SC AG266
已完成
2 期
A Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of 2 Doses of S-777469 in Patients With Atopic DermatitisAtopic DermatitisNCT00703573Shionogi209
已完成
2 期
Study To Evaluate Safety And Efficacy Of PF-06700841 In Subjects With Moderate To Severe Plaque PsoriasisChronic Plaque PsoriasisNCT02969018Pfizer212